As the Trump administration begins to make its mark on the Medicare drug price negotiation program and pursue its own policies on prescription drugs, litigation over program continues. In the two ...

Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...

The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost the Medicare program $8.8 billion over the course of about 10 years. That ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of the program’s price negotiations, touting a total of $12 billion saved ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. WASHINGTON — The Trump administration is ...

Medicare has completed its second round of price negotiations for 15 top-selling prescription drugs and posted maximum fair prices, per an Inflation Reduction Act provision. The announced net prices, ...

Medicare will save approximately $12 billion, or 44%, on 15 high-cost medications as a result of the second round of the program’s drug price negotiations, the Trump administration announced Tuesday ...

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...